Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DA-8010 DDI Study with Paroxetine or Mirabegron
NCT05992428Phase 1Completed
- Sponsor
- Dong-A ST
- Start
- Aug 2023
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of velufenacin in overactive bladder (OAB) (2 arms), sponsored by Dong-A ST. Primary endpoints: Peak Plasma Concentration and Area under the plasma concentration versus time curve. Started Aug 2023; status: completed.
02
Drugs
velufenacin
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on NCT05992428.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05992428.